Literature DB >> 28321142

Irinotecan Liposome Injection.

Danial E Baker, Terri L Levien.   

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433. The February 2017 monograph topics are bezlotoxumab, binimetinib, broadalumab, deuterabenazine, prasterone vaginal, and valbenazine. The DUE is on bezlotoxumab.

Entities:  

Year:  2017        PMID： 28321142      PMCID： PMC5345913          DOI： 10.1310/hpj5202-144

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  19 in total

Review 1.  Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Davendra P S Sohal; Pamela B Mangu; Alok A Khorana; Manish A Shah; Philip A Philip; Eileen M O'Reilly; Hope E Uronis; Ramesh K Ramanathan; Christopher H Crane; Anitra Engebretson; Joseph T Ruggiero; Mehmet S Copur; Michelle Lau; Susan Urba; Daniel Laheru
Journal:  J Clin Oncol       Date:  2016-05-31       Impact factor: 44.544

2.  Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion.

Authors:  Ashish V Kalra; Jaeyeon Kim; Stephan G Klinz; Nancy Paz; Jason Cain; Daryl C Drummond; Ulrik B Nielsen; Jonathan B Fitzgerald
Journal:  Cancer Res       Date:  2014-10-01       Impact factor: 12.701

3.  Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing's family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression.

Authors:  Min H Kang; Jing Wang; Monish R Makena; Joo-Sang Lee; Nancy Paz; Connor P Hall; Michael M Song; Ruben I Calderon; Riza E Cruz; Ashly Hindle; Winford Ko; Jonathan B Fitzgerald; Daryl C Drummond; Timothy J Triche; C Patrick Reynolds
Journal:  Clin Cancer Res       Date:  2015-03-01       Impact factor: 12.531

4.  Irinophore C™, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer.

Authors:  Robert Neijzen; May Q Wong; Navdeep Gill; He Wang; Tamanna Karim; Malathi Anantha; Dita Strutt; Dawn Waterhouse; Marcel B Bally; Isabella T Tai; Sylvia S W Ng; Donald T Yapp
Journal:  J Control Release       Date:  2014-12-08       Impact factor: 9.776

5.  Irinophore C: a liposome formulation of irinotecan with substantially improved therapeutic efficacy against a panel of human xenograft tumors.

Authors:  Euan C Ramsay; Malathi Anantha; Jason Zastre; Marieke Meijs; Jet Zonderhuis; Dita Strutt; Murray S Webb; Dawn Waterhouse; Marcel B Bally
Journal:  Clin Cancer Res       Date:  2008-02-15       Impact factor: 12.531

6.  Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors.

Authors:  Jeffrey R Infante; Vicki L Keedy; Suzanne F Jones; William C Zamboni; Emily Chan; Johanna C Bendell; Wooin Lee; Huali Wu; Satoshi Ikeda; Hiroshi Kodaira; Mace L Rothenberg; Howard A Burris
Journal:  Cancer Chemother Pharmacol       Date:  2012-09-02       Impact factor: 3.333

7.  Irinotecan Delivery by Lipid-Coated Mesoporous Silica Nanoparticles Shows Improved Efficacy and Safety over Liposomes for Pancreatic Cancer.

Authors:  Xiangsheng Liu; Allen Situ; Yanan Kang; Katie Rose Villabroza; Yupei Liao; Chong Hyun Chang; Timothy Donahue; Andre E Nel; Huan Meng
Journal:  ACS Nano       Date:  2016-02-09       Impact factor: 15.881

8.  A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer.

Authors:  A H Ko; M A Tempero; Y-S Shan; W-C Su; Y-L Lin; E Dito; A Ong; Y-W Wang; C G Yeh; L-T Chen
Journal:  Br J Cancer       Date:  2013-07-23       Impact factor: 7.640

9.  Irinophore C™, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities.

Authors:  Dawn N Waterhouse; Brent W Sutherland; Nancy Dos Santos; Dana Masin; Maryam Osooly; Dita Strutt; Christina Ostlund; Malathi Anantha; Natashia Harasym; Irina Manisali; Mohamed Wehbe; Marcel B Bally; Murray S Webb
Journal:  Invest New Drugs       Date:  2014-07-27       Impact factor: 3.850

10.  Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors.

Authors:  Huali Wu; Jeffrey R Infante; Vicki L Keedy; Suzanne F Jones; Emily Chan; Johanna C Bendell; Wooin Lee; Whitney P Kirschbrown; Beth A Zamboni; Satoshi Ikeda; Hiroshi Kodaira; Mace L Rothenberg; Howard A Burris; William C Zamboni
Journal:  Int J Nanomedicine       Date:  2015-02-10
View more
  1 in total

1.  The use of HEPES-buffer in the production of gallium-68 radiopharmaceuticals - time to reconsider strict pharmacopoeial limits?

Authors:  Jannie le Roux; Janke Kleynhans; Sietske Rubow
Journal:  EJNMMI Radiopharm Chem       Date:  2021-04-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.